"With the acquisition of Oxipit, we're adding a new dimension to our AI offering: autonomous AI that can genuinely reduce radiologists' workload in daily clinical practice. Equally important, we're acquiring the clinical validation and regulatory expertise required to deploy this category of AI responsibly at scale. The acquisition complements our vendor-neutral AI marketplace, which remains a cornerstone of our strategy, and our own rapid innovation such as MCP-powered system administration. Together, these moves demonstrate clear leadership in AI for diagnostic imaging and position us to help healthcare providers manage rising imaging volumes and address staff burnout," says Torbjörn Kronander, President and CEO of Sectra.

With the acquisition complete, Sectra now owns and will further develop ChestLink, Oxipit's flagship product and one of the most clinically validated examples of autonomous AI in radiology. Unlike conventional AI decision-support tools, which flag findings or assist prioritization but leave reporting to the radiologist, autonomous AI is developed and validated to independently complete a defined diagnostic task. ChestLink automatically identifies and clears high-confidence normal chest X-rays from the worklist, freeing radiologists to focus on cases with a higher probability of disease. The product holds CE Class IIb certification*, reflecting the rigorous safety and regulatory standards required for this category of AI.

Answers to frequently asked questions about the acquisition are available on our website>>.

* CE class IIb certification confirms compliance with EU medical device regulations and permits commercialization within the EEA.